FDA Advisers Back Pfizer Arthritis Drug

Reuters (05/09/12) Yukhananov, Anna
Pfizer has won support from a U.S. Food and Drug Administration advisory panel for its drug tofacitinib, a treatment for patients with rheumatoid arthritis who have not had success with at least one other drug for the disease. Analysts see tofacitinib as a potential blockbuster, with peak sales of $2 billion to $3 billion a year. If approved, the likely cheaper pill would compete with widely used injectable medicines.

Read the complete article


Share |

Sponsor Highlights

inPharmacyJobs